The storefront is a great spot for capturing Instagram-worthy photos, the store is filled with ... paraphernalia you could imagine, from unique logo wear and beach toys to their signature novelty ...

Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...

Teva (TEVA) is down -12.5%, or -$2.69 to $18.84. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year appears to have investors spooked. Teva on Wednesday reported that ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Learn more › You likely know Teva best for its extensive sandals, which it has been making since the mid-’80s. Now, the company has released its first truly winterized hiking boots ...

Good morning, everybody. I'm Chris Schott from J.P. Morgan and it's my pleasure to be introducing Teva today at the J.P. Morgan Healthcare Conference. From the company we have the CEO, Richard ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...